Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 8, 2013
Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detectionSerge A L Zander, Jos H Beijnen, Olaf van TellingenPlos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.Vaccines|July 27, 2024
Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based VaccineSebenzile K Myeni, Anouk A Leijs, Peter J Bredenbeek, et al.Cancer Research|February 11, 2010
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecanSerge A L Zander, Ariena Kersbergen, Eline van der Burg, et al.Nature Communications|February 28, 2023
Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinaseSebenzile K Myeni, Peter J Bredenbeek, Robert C M Knaap, et al.Journal of Biological Rhythms|June 26, 2023
Impact of Simulated Rotating Shift Work on Mammary Tumor Development in the p53R270H©/+WAPCre Mouse Model for Breast CancerAstrid A Streng, Kirsten C G Van Dycke, Conny T M van Oostrom, et al.Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.Pageof 1